Business Wire

THE-BRAIN-FORUM

Share
Lausanne to Be the Epicentre of Brain Research in May 2016

The Brain Forum brings together top scientists and entrepreneurs from the world’s biggest brain initiatives. The event will run in collaboration with EPFL on 26 and 27 May at the SwissTech Convention Center in Lausanne, Switzerland.

Launched in 2013, The Brain Forum plays an important role in the progression of brain research by connecting researchers, engineers, healthcare professionals, entrepreneurs, investors, funding agencies and policy makers. In so doing, The Brain Forum helps to accelerate our understanding of the brain by translating science from bench to business, thus making laboratory innovations available to all.

Dr. Jamil El-Imad, CEO of The Brain Forum, comments: “We want to include anyone with an interest in the brain. We hope that our different but complementary experience and perspectives can help to overcome the biggest challenges of this era. You can’t build the future based on present assumptions so we need to develop our thinking and be open to spontaneous opportunities that may lead to the necessary serendipity for innovation.”

The Brain Forum has proven a great success in previous years. This year the main objectives are to enhance the attendance of the international community, to promote awareness of brain science at a global level and to stimulate worldwide, unified efforts to tackle one of the biggest healthcare challenges of this century. The event features an impressive line-up of world-renowned experts who promise to give fascinating insights into cutting-edge research, advancements in our understanding of the brain and the impact of that knowledge. International brain initiatives and regulatory bodies from the EU, USA, Japan and China will share how they are working towards improving brain research. Google will host a special session on ‘Lessons from practical machine intelligence’ followed by UBS on ‘The Workforce of the Future,’ while the popular start-up competition returns offering opportunities for start-ups to pitch to investors looking to invest in the solutions of the future.

The Brain Forum was created because scientific exploration of the brain is fundamental for tackling the challenges of the 21st century. As more and more people are affected by neurological and psychiatric conditions, there is increasing awareness of the importance of brain research to healthcare and technology. WHO recently concluded that brain disorders account for 35 per cent of the burden of all diseases in Europe and will become the major medical need of this century. In 2010, the European Brain Council published a report demonstrating that brain disorders cost Europe EUR 800 billion in 2010 – more than cardiovascular disease, cancer and diabetes combined.

Dr. El-Imad adds: “The future is both terrific and terrifying. Our aging populations are increasing the incidence and burden of many neurological and psychiatric diseases presenting huge challenges for healthcare and society, while artificial intelligence will presage a new industrial revolution, altering the workforce of the future and shifting further the balance of humans vs. machines. Technology and science will allow us to do things that we never imagined possible, but we as a society need to be prepared to deal with the consequences – good and bad – of our rapidly changing future.”

To participate - and mould the future of brain science – register at:
www.thebrainforum.org

*Source: ME NewsWire

Contact:

Headline office
The Brain Forum
Christophe Tournier, press office, +412-1517-6717
thebrainforum@farner.ch

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zycus Named a LEADER in 2025 IDC MarketScape for Source-to-Pay7.7.2025 15:41:00 CEST | Press release

Zycus, a global leader in AI-powered procurement technology, has been named a Leader in the IDC MarketScape: Worldwide AI-Enabled Source-to-Pay 2025 Vendor Assessment. This recognition follows a comprehensive evaluation, including RFI submissions, live product demos, analyst briefings, and customer interviews. “Zycus is a recognized Leader in the Source-to-Pay space leveraging Agentic AI to drive procurement transformation. With AI agents like Merlin Intake and the Autonomous Negotiation Agent (ANA), Zycus offers a seamlessly integrated solution suite for enterprises focused on cost savings, risk mitigation, and scalability,” — Patrick Reymann, Research Director, IDC “We believe this recognition underscores our commitment to empowering procurement teams through Merlin Agentic Platform, deep domain expertise, and customer-first innovation,” said Aatish Dedhia, Founder & CEO, Zycus. “With a global product footprint spanning every aspect of the S2P lifecycle, Zycus is proud to support ent

Kevin Egan Joins ClickHouse as Chief Revenue Officer to Accelerate Growth7.7.2025 15:00:00 CEST | Press release

ClickHouse, a leader in real-time analytics, data warehousing, observability, and AI/ML, today announced the appointment of Kevin Egan as Chief Revenue Officer (CRO). With over two decades of experience building and leading enterprise sales organizations at Atlassian, Slack, Dropbox, and Salesforce, Egan will oversee ClickHouse’s global go-to-market functions as demand continues to grow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707959780/en/ Aaron Katz, ClickHouse CEO with Kevin Egan, ClickHouse CRO “I’m incredibly excited to join ClickHouse at such a pivotal time,” said Egan. “As organizations navigate how to compete and thrive in the AI era, ClickHouse is emerging as the de facto database powering the real-time, scalable analytics that AI-driven applications demand. I look forward to building strong relationships not only with forward-thinking customers, but also with our channel and technology partners—working to

Accellix Appoints Dr. Félix A. Montero-Julian as Vice President of Scientific Affairs7.7.2025 14:00:00 CEST | Press release

Accellix, a global leader in rapid point of need cytometry solutions, is pleased to announce the appointment of Félix A. Montero-Julian, PhD as Vice President of Scientific Affairs. Dr. Montero-Julian brings more than 30 years of international experience in scientific affairs, analytical development, and regulatory science to support Accellix’s strategic vision and innovation roadmap. Dr. Montero-Julian joins Accellix from bioMérieux, where he most recently served as Scientific Senior Director of Pharma Quality Control. His previous roles include Cytometry R&D Director at bioMérieux and Director of the Cellular Analysis Department at Beckman Coulter, underscoring a distinguished track record spanning biopharmaceuticals, industrial microbiology, and clinical diagnostics. “I’m excited to join Accellix during this period of dynamic growth and innovation,” said Dr. Montero-Julian. “I have great confidence in the potential of the Accellix Platform to transform quality control in cell and ge

NTT DATA Appoints Anne-Sophie Lotgering as Europe CEO7.7.2025 13:00:00 CEST | Press release

Lotgering brings over two decades of leadership experience in IT services and telecommunications.Her career spans senior roles at The Orange Group and Microsoft. NTT DATA, a global leader in digital business and technology services, today announced the appointment of Anne-Sophie Lotgering as the new Chief Executive Officer for Europe at NTT DATA, Inc., effective 1 September 2025. Lotgering succeeds Chieri Kimura and will report directly to NTT DATA, Inc. President and Global CEO, Abhijit Dubey. She will also join NTT DATA, Inc.’s Executive Leadership Team. Lotgering brings over two decades of leadership experience in IT services and telecommunications, with a strong track record in B2B2C and B2B sales, digital marketing and transformation. She joins NTT DATA from Proximus NXT IT where she served as CEO, overseeing the IT integration of B2B operations across the Netherlands, Luxembourg, and Belgium. Her recent achievements include the successful unification of multiple subsidiaries into

CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology7.7.2025 13:00:00 CEST | Press release

CorFlow Therapeutics AG (CorFlow), a pioneering company in the field of cardiac care targeting microvascular disease, today announced that the U.S. Food & Drug Administration (FDA) has approved the company’s technology for investigational device exemption (IDE), which allows the pivotal clinical trial to begin at U.S. hospitals. CorFlow will now prepare these clinical trial sites to receive CorFlow systems, undergo training and begin enrolling patients being treated for heart attacks. The IDE Pivotal Trial, MOCA-II, is intended to prospectively validate the diagnostic accuracy of the proprietary CorFlow CoFl system in determining the presence or absence of microvsacular obstruction (MVO) during a primary PCI procedure. The primary endpoint compares the CoFI diagnostic reading to a reference standard of diagnosis by a cardiac MRI scan. The trial is approved to enroll over 200 STEMI patients at prestigious research institutions in both the United States and Europe. Having successfully co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye